Locations:
SearchAdvertisement
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients
Two-year event-free survival comparable to matched sibling donor myeloablative transplant
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival
Improvements enable targeting of brain tumors with single-session, fractionated or neoadjuvant approaches
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients
Consult program a valuable tool that benefits both patients and clinicians
Additional fine-tuning and recruiting of new patient groups underway
Advertisement
Advertisement